Clinical trial · Interventional
Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors
NCT04414020CI-TRIAL-00045419unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neuronal injury is evident in elective craniotomy for space occupying lesions. Surgical trauma and mechanichal impact of the tumor causes neuronal injury. Neurosreroid progesterone is a neurotransmittern , trail to use in abolishing neurotoxcicty
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Traumatic Cerebral Edema | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Progesteron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- description
- Control group receiving conventional treatment without progesterone
- type
- ACTIVE_COMPARATOR
- label
- progesterone group
- description
- 1mg pregesterone intramusculer given 7 days pre and post operative , Biopsy was achieved from brain tumor interface
- interventionNames
- Drug: Progesteron
Primary outcomes (1)
- measure
- Number of Participants With craniotomy-Related Adverse Events
- timeFrame
- 3 months
- description
- Degree of microscopic cellular injury and brain odema in brain biopsy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * All elective brain tumors elligible for craniotomy Exclusion Criteria: * Refusal to participare * Emergency craniotomy
References
Publications (0)
Data not yet available
No reference posted for this study.